Cover Image
Market Research Report

Cancer Immunotherapy Markets, The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics including Executive and Consultant Guides and a Complete Listing of Active Company Summaries. 2019 to 2023

Published by Howe Sound Research Product code 854113
Published Content info 351 Pages
Delivery time: 1-2 business days
Price
Back to Top
Cancer Immunotherapy Markets, The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics including Executive and Consultant Guides and a Complete Listing of Active Company Summaries. 2019 to 2023
Published: June 2, 2019 Content info: 351 Pages
Description

OVERVIEW:

“Disruptive technology to change therapeutics .....”

The technologies and opportunities are explored. Over one hundred companies are profiled. Our research makes you the expert.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. This is a complex area but our readable reports help you understand it, both the technology and the opportunity.

The technology is moving faster than the market. Already worth billions the global market is poised for dramatic growth. Is the cure in sight? The impact on the health care industry is enormous. The report forecasts the market size out to 2023.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

CAR - T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School
Table of Contents

Table of Contents

i. Market Guides

  • iA. Situation Analysis
  • iB. Guide for Executives and Marketing Staff
  • iC. Guide for Investment Analysts and Management Consultants
  • iD. Impact of The Nobel Prize

1. Introduction and Market Definition

  • 1.1. What is Cancer Immunotherapy?
  • 1.2. Immunotherapy - the looming cure
  • 1.3. Market Definition
    • 1.3.1. Market Size
    • 1.3.2. Currency
    • 1.3.3. Years
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. U.S. Medical Market and Pharmceutical Spending - Perspective
    • 1.5.1. U.S. Expenditures for Pharmaceuticals

2. Immunotherapy - Guide to Immune Technologies

  • 2.0. The Immune System
    • 2.0.1. Innate immune system
      • 2.0.1.1. Surface barriers
      • 2.0.1.2. Inflammation
      • 2.0.1.3. Complement system
      • 2.0.1.4. Cellular barriers
      • 2.0.1.5. Natural killer cells
    • 2.0.2. Adaptive immune system
      • 2.0.2.1. Lymphocytes
      • 2.0.2.2. Killer T cells
      • 2.0.2.3. Helper T cells
      • 2.0.2.4. Gamma delta T cells
      • 2.0.2.5. B lymphocytes and antibodies
    • 2.0.3. Tumor immunology - the immune surveillance system
  • 2.1. Immuno Oncology Technologies
    • 2.1.1. Monoclonal Antibodies
      • 2.1.1.1. Outlook for Monoclonal Antibodies
      • 2.1.1.2. Companies with Monoclonal Antibodies in their Pipeline
    • 2.1.2. Cancer vaccines
      • 2.1.2.1. Outlook for Cancer Vaccines
      • 2.1.2.2. Companies with Cancer Vaccines in their Pipeline
    • 2.1.3. Cytokines
      • 2.1.3.1. Outlook for Cytokines
      • 2.1.3.2. Companies with Cytokines in their Pipeline
    • 2.1.4. Cell Based Therapies
      • 2.1.4.1. Outlook for Cell Based Therapies
      • 2.1.4.2. Companies with Cell Based Therapies in their Pipeline
    • 2.1.5. Inhibitors/Agonists
      • 2.1.5.1. Outlook for Inhibitors/Agonists
      • 2.1.5.2. Companies with Inhibitors/Agonists in their Pipeline
    • 2.1.6. Antibody Drug Conjugates
      • 2.1.6.1. Outlook for Antibody Drug Conjugates
      • 2.1.6.2. Companies with Antibody Drug Conjugates in their Pipeline
    • 2.1.7. Others
      • 2.1.7.1. Outlook for Other Therapeutics
      • 2.1.7.2. Companies with Viral Therapeutics in their Pipeline
      • 2.1.7.3. Companies with Other Therapeutics in their Pipeline

3. Industry Overview

  • 3.1. Market Players - Roles & Impacts
    • 3.1.1. Drug manufacturers - Larger/pharmaceutical
    • 3.1.2. Drug manufacturers - Generic
    • 3.1.3. Contract Research and Manufacturing
    • 3.1.4. In Vitro Diagnostics Industry
    • 3.1.5. Drug Marketing Companies
    • 3.1.6. Biotechnology Companies
    • 3.1.7. Regulatory Bodies

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Outcome potential
    • 4.1.2. Fast tracking
    • 4.1.3. Funding
    • 4.1.4. Technology Environment
    • 4.1.5. Target Solutions
  • 4.2. Factors Limiting Growth
    • 4.2.1. Cost of Treatment
    • 4.2.2. Clinical Trials Role
    • 4.2.3. Combinations
    • 4.2.4. Protocols
  • 4.3. Therapeutic Technology Development
    • 4.3.1. Combinations - Issues and Complexity
    • 4.3.2. Preference for a drug
    • 4.3.3. Problems of Immunity Engineering
    • 4.3.4. The Role of Cost
    • 4.3.5. The Disruption Dynamic
    • 4.3.6. CAR-T Cell Therapy
    • 4.3.7. The Next Five Years

5. Cancer Immunotherapy Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
      • Gritstone to Move Slate Immunotherapy into Clinical Trial
      • Personalis, Inc. to Provide Tumor Immunogenomic Profiling to the Parker Institute for
      • Immunotherapy Biomarker Discovery in Clinical Trial Participants
      • Spectrum Announces a Novel Immuno-Oncology Platform including Two Early Stage Assets
      • FDA Approves Tecentriq/Chemo for Newly Diagnosed Extensive-stage SCLC
      • Keytruda Better Than Chemotherapy
      • Cancer ‘vaccine' eliminates tumors in mice
      • Iovance Rides The T-Cell Wave
      • Overcoming the Current Limitations of Cancer Immunotherapy
      • Startup focused on cell therapy gets acquired
      • Positive results in pre-clinical trials for Imugene's cancer vaccine
      • Celsion Corporation OPTIMA Study Continues
      • Regeneron and bluebird bio to Collaborate on Cancer Immunotherapy
      • Sangamo bulks up in cell therapy with TxCell acquisition
      • BI dives deeper into cancer immunotherapy with new acquisition
      • Innovest Global Acquires Stake in StemVax Therapeutics
      • Eli Lilly Acquires Pegilodecakin, Potential Immunotherapy Now in Phase 3 Trial
      • FDA Grants Breakthrough Therapy Designation to Lenvima-Keytruda Combo
      • FDA Grants Fast Track Designation to Galinpepimut-S for Treating Multiple Myeloma
      • BioLineRx Initiates Phase 1/2a Trial Testing AGI-134 in Metastatic Solid Tumors
      • FDA OKs Phase 1 Trial to Test Celyad's Donor-derived CAR T-cell Therapy in Colorectal
      • Cancer
      • Vyriad Expands Phase 1 Trial to Test Voyager-V1 in Combination with Bavencio for
      • Colorectal Cancer
      • FDA Expedites Tecentriq-Avastin Combo for Most Common Liver Cancer
      • Immunotherapy Use Can Double Survival Rate of Melanoma Patients with Brain Metastasis
      • FDA Grants Priority Review to Keytruda-Chemo Combo for Metastatic NSCLC
      • FDA Approves Phase 2 Trial Testing AIVITA's Vaccine for Aggressive Brain Cancer
      • Immunotherapy Candidate M7824 Effective in Advanced Lung Cancer Patients
      • Apogenix Prepares Submission for Conditional Marketing Authorization in Europe
      • Immunotherapy Leads to Complete Response in Advanced Breast Cancer Patient
      • Keytruda Beats Chemo at Increasing NSCLC Patients' Survival, Phase 3 Trial Shows
      • CBT Pharmaceuticals and CrystalGenomics Announce Partnership
      • New cancer vaccine against melanoma has 100% success rate

6. Profiles of Key Immunotherapy Companies

  • 10X Genomics
  • A. Menarini
  • AbbVie
  • Ablynx
  • Adaptimmune Therapeutics PLC
  • ADC Therapeutics
  • Aduro Biotech Inc.
  • Agenus Inc.
  • AIVITA Biomedical
  • Aleta Biotherapeutics
  • Amgen
  • Antigen Express Inc
  • Apeiron Biologics
  • Apogenix GmbH
  • Aptose Biosciences
  • Arcus Biosciences Inc.
  • Astrazeneca PLC
  • Atara Biotherapeutics
  • Atlas Venture
  • Aurora Biopharma
  • Autolus Therapeutics plc
  • Beigene Ltd.
  • Bellicum Pharmaceuticals
  • BioLineRx
  • BioNTech
  • Biovest International Inc
  • Bluebird bio
  • BriaCell Therapeutics
  • Bristol-Myers Squibb
  • CARsgen Therapeutics
  • CBT Pharmaceuticals
  • Celgene
  • Celldex Therapeutics
  • Cellectis S A
  • Cellular Biomedicine
  • Celsion Corporation
  • Celyad
  • Chugai Pharmaceutical Co.
  • Compugen
  • CrystalGenomics
  • Cytomx Therapeutics Inc.
  • Cytovac A/S
  • Daiichi Sankyo
  • Dendreon
  • Dynavax Technolgy
  • Eisai
  • Eli Lilly and Co.
  • EMD Serono Inc
  • eTheRNA
  • Fate Therapeutics Inc.
  • Five Prime Therapeutics Inc.
  • F-star
  • Gadeta
  • Galectin Therapeutics
  • Genentech Inc
  • Genmab AS
  • Genprex
  • Gilead Sciences Inc.
  • GlaxoSmithKline
  • Gliknik Inc
  • GlobeImmune Inc
  • Glycostem
  • Gritstone Oncology, Inc
  • Heat Biologics Inc
  • Heidelberg Pharma GmbH
  • Idera Pharmaceuticals, Inc
  • Immatics Biotechnologies GmbH
  • Immudex
  • Immune Design
  • Immunomedics
  • Imugene
  • Incyte Corporation
  • Inmune Bio Inc.
  • Innate Pharma
  • Iovance Biotherapeutics Inc.
  • iOx Therapeutics
  • iTeos Therapeutics
  • Janssen Global Services (J&J)
  • Jounce Therapeutics
  • Juno Therapeutics
  • Kite Pharma Inc
  • KSQ Therapeutics
  • Life Science Pharmaceuticals
  • MabVax Therapeutics Holdings Inc
  • Macrogenics Inc.
  • MedImmune LLC
  • Merck & Co., Inc
  • Mirati Therapeutics
  • Moderna Therapeutics
  • Morphosys AG
  • Morphotek Inc
  • Myriad RBM
  • Mustang Bio
  • Nanjing Legend Biotech
  • Nantkwest
  • NBE Therapeutics
  • Nekonal Oncology
  • Nektar Therapeutics
  • Neon Therapeutics
  • NewLink Genetics Corp
  • Nilogen
  • Noile-Immune Biotech
  • Northwest Biotherapeutics Inc
  • Novartis A G
  • Novelogics Biotechnology, Inc.
  • Novo Nordisk
  • OncoPep Inc
  • OSE Immunotherapeutics
  • Oxford BioTherapeutics Ltd
  • Personalis
  • Pfizer
  • Pieris Pharmaceuticals
  • Pique Therapeutics
  • Progenics
  • PsiOxus
  • Qiagen
  • Recepta Biopharma
  • Regen Biopharma Inc
  • Regeneron Pharmaceuticals
  • Rift Biotherapeutics
  • Roche Holdings Inc
  • Sanofi
  • Seattle Genetics
  • Sellas
  • Sesen Bio
  • Shattuck Labs
  • Siva Therapeutics
  • Sorrento Therapeutics Inc.
  • SOTIO a.s
  • Spectrum Pharmaceuticals
  • StemVax Therapeutics
  • Surface Oncology
  • Sydys Corporation
  • Syndax Pharmaceuticals
  • Takeda Oncology
  • TapImmune Inc
  • TCR2 Therapeutics
  • Tesaro
  • TG Therapeutics
  • ThioLogics Ltd
  • Tocagen
  • Transgene SA
  • Unum Therapeutics
  • Verastem
  • Virttu Biologics
  • Vyriad
  • Xencor Inc.
  • Ziopharm Oncology Inc
  • Zymeworks Inc.
  • 6.200 Company Pipelines Analysis
  • 6.200.1 All Companies, Pipeline Activity Summary by Technology and Phases

7. Global Market Size

  • 7.1. Cancer Immunotherapy Global Market Size by Country with Charts
  • 7.2. Cancer Immunotherapy Global Market Size by Technology with Charts
  • 7.3. Cancer Immunotherapy Global Market Size by Cancer with Charts

8. Global Market by Technology

  • 8.1. Monoclonal Antibody Market
    • 8.1.1. Monoclonal Antibody Market by Country
  • 8.2. Cancer Vaccine Market
    • 8.2.1. Cancer Vaccine Market by Country with Chart
  • 8.3. Cytokines Market
    • 8.3.1. Cytokines Market by Country with Chart
  • 8.4. Cell Based Market
    • 8.4.1. Cell Based Market by Country with Chart
  • 8.5. Inhibitor Agonist Market
    • 8.5.1. Inhibitor Agonist Market by Country with Chart
  • 8.6. Other Market
    • 8.6.1. Other Market by Country with Chart

9. Cancer Immunotherapy Market by Cancer Type

  • 9.1. Lung Cancers Market
    • 9.1.1. Lung Cancers Market by Country
  • 9.2. Breast Cancers Market
    • 9.2.1. Breast Cancers Market by Country with Chart
  • 9.3. Blood Cancers Market
    • 9.3.1. Blood Cancers Market by Country with Chart
  • 9.4. Colorectal Cancers Market
    • 9.4.1. Colorectal Cancers Market by Country with Chart
  • 9.5. Prostate Cancers Market
    • 9.5.1. Prostate Cancers Market by Country with Chart
  • 9.6. Other Cancers Market
    • 9.6.1. Other Cancers Market by Country with Chart

10. Appendices

  • 10.1. FDA Cancer Drug Approvals by Year
  • 10.2. Clinical Trials Started 2010 to 2016
  • 10.3. Prevalence of Cancer Treatments - 2015

Table of Tables

  • Table 1: List of Cancers by Mortality
  • Table 2: Overview of Innate and Adaptive Immunity
  • Table 3: FDA Approved Monoclonal ANTIBODIES in Cancer treatment
  • Table 4: Monoclonal Antibody Companies
  • Table 5: Cancer Vaccine Companies
  • Table 6: Cytokine Companies
  • Table 7: Cell Based Therapy Companies
  • Table 8: Inhibitor/Agonist Companies
  • Table 9: Antibody Drug Conjugate Companies
  • Table 10: Viral Therapeutics Companies
  • Table 11: Other Therapeutics Companies
  • Table 12: Market Players by Type
  • Table 13: Five Factors Driving Growth
  • Table 14: Four Factors Limiting Growth
  • Table 15: Pipeline Snapshot, All Companies. Technologies Trials by Phases
  • Table 16: Cancer Immunotherapy Global Market by Country/Region
  • Table 17: Cancer Immunotherapy Global Market by Technology
  • Table 18: Cancer Immunotherapy Global Market by Cancer
  • Table 19: Monoclonal Antibody Market by Country
  • Table 20: Cancer Vaccine Market by Country
  • Table 21: Cytokines Market by Country
  • Table 22: Cell Based Market by Country
  • Table 23: Inhibitor Agonist Market by Country
  • Table 24: Other Market by Country
  • Table 25: Lung Cancers Market by Country
  • Table 26: Breast Cancers Market by Country
  • Table 27: Blood Cancers Market by Country
  • Table 28: Colorectal Cancers Market by Country
  • Table 29: Prostate Cancers Market by Country
  • Table 30: Other Cancers Market by Country

List of Figures

  • Figure 1: Pharmaceutical Expenditures 2010 to 2020 ($Billion)
  • Figure 2: Helper T Cell Roles
  • Figure 3: Antibody Diagram
  • Figure 4: Macrophages attack a Cancer Cell
  • Figure 5: CAR-T Clinical Trials
  • Figure 6: Cell Therapy Trial Results
  • Figure 7: Antibody Drug Conjugate Diagram
  • Figure 8: Growth rates of IO Technologies
  • Figure 9: Technology Trials by Phase
  • Figure 10: Market Size by Country - Key Countries
  • Figure 11: Global Market by Country
  • Figure 12: Chart of Global Market by Technology
  • Figure 13: Growth Rates of Technology Segments
  • Figure 14: Chart of Global Market by Cancer
  • Figure 15: Chart - Monoclonal Antibody Market by Country
  • Figure 16: Chart - Cancer Vaccine Market by Country
  • Figure 17: Chart - Cytokines Market by Country
  • Figure 18: Chart - Cell Based Market by Country
  • Figure 19: Chart - Inhibitor Agonist Market by Country
  • Figure 20: Chart - Other Market, Global Size
  • Figure 21: Chart - Lung Cancers Market by Country
  • Figure 22: Chart - Breast Cancers Market by Country
  • Figure 23: Chart - Blood Cancers Market by Country
  • Figure 24: Chart - Colorectal Cancers Market by Country
  • Figure 25: Chart - Prostate Cancers Market by Country
  • Figure 26: Chart - Other Cancers Market by Country
  • Figure 27: FDA Cancer Drug Approvals by Year
  • Figure 28: Clinical Trials for Immunotherapy by Year
  • Figure 29: Pie Chart of Prevalence of Cancer Treatments
Back to Top